‘Dark spots': COVID jab tied to rare health symptom
While vaccines have been vital in fighting the pandemic, emerging data could mean we're not out of the woods yet.
Between January 2021 and January 2023, 20 peer-reviewed studies looked into eye problems reported by 243 people aged 18 to 84 who had received COVID-19 vaccines.
Almost half of these patients - 42 per cent - had the Pfizer-BioNTech jab, which was the main vaccine rolled out in Australia, the USA, the UK, and much of Europe.
What jumps out is inflammation. Nearly half of the patients reported experiencing ocular inflammatory conditions like uveitis, an irritation deep inside the eye.
Another 24 per cent were said to have suffered optic neuritis, a swelling of the optic nerve that can cause pain and threaten vision.
Herpetic eye disease, caused by the herpes virus attacking the eye, showed up in 14 per cent of cases, triggering redness, pain, and discomfort.
About 10 per cent documented retinal circulation issues - blockages in the eye's arteries or veins that can trigger sudden vision loss.
And there were also a few rare cases where patients were noted to exhibit retina-related problems causing 'dark spots' or 'blind patches'.
But the most notable observations come from a recent Turkish study that tracked 64 patients before and after their two mRNA vaccine doses.
Using detailed eye scans, researchers found an 8 per cent drop in the cornea's endothelial cell count - the cells responsible for keeping the cornea clear.
These cells don't regenerate, and losing too many can permanently impair vision.
To put that into perspective, healthy adults usually have between 2000 and 3000 of these cells per square millimetre.
After vaccination, the average dropped from 2597 to 2378.
While these numbers are still considered safe for most, the decline could be a warning sign for people with pre-existing eye conditions or those who have had eye surgeries like LASIK, cataract removal, or corneal transplants.
Researchers also noted that corneas thickened by around 2 per cent after vaccination - a sign of possible swelling.
The honeycomb shape of the endothelial cells became distorted, and the size differences between individual cells increased, which are both signs of cellular stress.
Though none of the study participants reported immediate vision problems, experts warn that long-term structural changes to the cornea could lead to lasting damage, especially in vulnerable patients.
Dr Fatma Sümer and Sevgi SubaÅŸi, authors of the study published in Ophthalmic Epidemiology, stressed the need for careful observation: 'The endothelium should be closely monitored in those with a low endothelial count or who have had a corneal graft.'
According to Healthline, eye complications after vaccination are rare and appear to be driven by an overactive immune response.
Symptoms can include blurred vision, light sensitivity, redness, eye pain, shingles around the eye, or reactivated herpes infections.
In even rarer cases, the immune system may reject a previously transplanted cornea, risking vision loss and graft failure.
This means the transplanted cornea loses its clarity and function, leading to impaired vision and the potential need for further treatment or surgery.
These findings are not conclusive, and experts do not advise people to skip their COVID vaccine shots — far from it.
But they are urging doctors and patients to not ignore these subtle warning signs.
Those who have had prior eye surgery, suffer from chronic eye disease, or notice persistent blurry vision after vaccination are advised to be checked, because even small changes inside your eyes can have big consequences down the road
According to safety reports from the Therapeutic Goods Administration (TGA), 'vaccination is the most effective way to reduce deaths and severe illness from infection.'
Like all medicines, the TGA notes, 'COVID-19 vaccines may cause some side effects.
'The most frequently reported include injection-site reactions (such as a sore arm) and more general symptoms, like headache, muscle pain, fever and chills.'
The TGA closely monitors reports of adverse events to the COVID-19 vaccines and emphasises that 'the protective benefits of vaccination far outweigh the potential risks.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

News.com.au
10 minutes ago
- News.com.au
ASX Health Quarterly Wrap: Control Bionics makes 15pc sales revenue jump
As July draws to a close, today marks the official end of the June quarterly reporting period under ASX Listing Rules. These updates provide investors with a valuable snapshot of business momentum and future prospects with investors in healthcare watching signs of revenue growth, cash burn and future strategic direction. The June results are particularly pertinent as the last quarter of the financial year in Australia, providing an overview of the full year for many companies. Control Bionics (ASX:CBL) Control Bionics delivered a record year, with unaudited sales revenue rising 15% to more than $6 million and total revenue exceeding $7m in FY25. The company also reported an 8% lift in cash receipts, reaching $5.7m. During the quarter Control Bionics officially launched its NeuroNode Only sales model in the US following issuance of US Medicare reimbursement code E2513 under the Healthcare Common Procedure Coding System (HCPCS), locking in a rate of US$4300 (A$6600) per device. NeuroNode is a wearable, watch-like, wireless non-invasive electromyography (EMG) or spatial sensor device to assist people with physical disabilities perform everyday functions. Notably, this includes sufferers of cerebral palsy or motor neurone disease. Control Bionics said the US HCPCS reimbursement code laid the foundation for continued growth in the US, its largest addressable market. Discussions with multiple potential distribution partners in the US are well advanced. Control Bionics' Neuro Elite Athletics program NeuroBounce continues to gain commercial traction, diversifying its EMG technology into the sports performance market. Control Bionics has launched NeuroBounce in Australia with all five athletes in the initial four-week program improving their vertical jump height, with one recording an increase of 14 centimetres. Meanwhile, the company's NeuroNode device continues to gain traction in global markets. Following adoption within the UK's National Health Service (NHS), Control Bionics is now in active partnership discussions in both Europe and the US as it builds out its distribution-only strategy. In its NeuroStrip product line, Control Bionics has begun collecting EMG-labelled data from athletes and rehabilitation facilities with its development team now assessing opportunities to incorporate AI solutions to automate elements of the system. NeuroStrip hardware is now in use in both Australia and the US, with clinical evaluations underway across several areas. With growing international interest, expanding product lines, and a clear focus on commercialisation, Control Bionics said it had entered FY26 with strong momentum and multiple catalysts for further growth. Alterity Therapeutics (ASX:ATH) CEO and managing director Dr David Stamler said US Food and Drug Administration (FDA) fast track designation for ATH434 in multiple system atrophy (MSA) was the highlight of the recent quarter that also featured additional positive clinical data from its Phase 2 double-blind trial. "Receiving fast track designation alongside the orphan drug designation we have already received underscores the promise of this potentially disease-modifying therapy to address the urgent needs of individuals with MSA," he said. "In addition, we presented additional efficacy data from the ATH434-201 double-blind trial at prominent medical meetings, including slowing of disease progression on the Unified MSA Rating Scale or UMSARS, improvement in key symptoms of MSA, and preserved activity in the outpatient setting." Following quarter end Alterity this week announced positive results from its ATH434-202 open-label phase II clinical trial, in which ATH434 demonstrated a clinical benefit on the UMSARS and global assessments of neurological symptoms. Neuroimaging biomarkers showed target engagement and slowed brain atrophy in a manner consistent with the double-blind study findings with ATH434 continuing to demonstrate a favourable safety profile. "These data reinforce our confidence in the MSA program as we prepare for interactions with the US FDA," Stamler said. Alterity's cash position on June 30 was $40.66m, with operating cash outflows for the quarter of $2.35m. Neurotech International (ASX:NTI) Positive human PK study results for NTI164 released in June following preclinical toxicology results in May Data from Rett Syndrome program presented at the International Rett syndrome Foundation (IRSF) Annual Scientific Meeting Neurotech initiated formal engagement with US FDA in preparation for lodging an investigational new drug (IND) application in FY26 Neurotech's June quarter was marked by important clinical progress, growing international recognition, and further regulatory engagement for its lead investigational therapy NTI164, a proprietary CBDA-rich cannabinoid formulation being developed for paediatric neurological and inflammatory brain disorders. The company completed its first-in-human pharmacokinetic (PK) study. Conducted in healthy adult volunteers, the study confirmed that NTI164 is rapidly and predictably absorbed, with CBDA reaching peak plasma levels within 2–4 hours and emerging as the dominant circulating cannabinoid. Neurotech said the results validated NTI164's systemic stability, safety, and potential suitability for paediatric use. The PK study builds on preclinical toxicology results released in May, which demonstrated excellent tolerability in rats and dogs under GLP conditions. Neurotech also presented data from its Rett syndrome program at the International Rett Syndrome Foundation (IRSF) Annual Scientific Meeting in Boston. Following the quarter, Neurotech announced that results from its phase I/II open-label clinical trial in Rett syndrome had been published in the Journal of Paediatrics and Child Health, a peer-reviewed scientific journal. Neurotech continued to progress its dual regulatory pathway strategy in Australia and the US during the quarter. In Australia, the company is moving toward potential product registration with the therapeutic Goods Administration (TGA) and is exploring expedited approval options to support timely market entry. The company has initiated formal engagement with the FDA in preparation for lodging an investigational new drug (IND) application in FY26. In June, Neurotech appointed leading US clinician Dr Bonni Goldstein as chief medical advisor USA, who has more than 25 years of clinical experience, including 17 years specialising in cannabinoid-based medicine. Goldstein is internationally recognised as a pioneer in paediatric cannabinoid therapy and brings key expertise as NTI164 progresses its development pathway. Also in June, CEO Dr Anthony Filippis attended the BIO International Convention in Boston as Neurotech continues to elevate its global profile and explore partnering and funding opportunities. Neurotech placed its wholly owned subsidiaries AAT Medical Ltd and AAT Research Ltd, responsible for the Mente neurofeedback device, into voluntary liquidation. The move reflects the company's focus on advancing NTI164. Operating cash outflows for the quarter were $2.6m, primarily driven by R&D expenditure supporting its FDA IND and TGA submissions, as well as clinical trial extension costs. Neurotech ended the period with $3m in cash and expects reduced outflows in Q1 FY26. A ~$3m R&D tax refund is anticipated in Q1 or early Q2 FY26 to further bolster cash reserves.


SBS Australia
27 minutes ago
- SBS Australia
Hepatitis: Warning for migrant communities of impact of this silent killer
LISTEN TO SBS Indonesian 04:48 Indonesian Almost 300,000 people in Australia are living with Hepatitis B or Hepatitis C - often without warning signs of liver damage. It found that 69 people will live with Hepatitis B and almost a quarter with Hepatitis C. Hepatitis C is curable, but there is no vaccine yet. Meanwhile Hepatitis B has a vaccine and treatment, but there is no cure yet. Eradicating viral hepatitis as a public health threat is a key goal, with almost 1,000 deaths in Australia recorded each year. Listen to SBS Indonesian every Monday, Wednesday, Friday and Sunday at 3pm. Follow us on Facebook and Instagram , and don't miss our podcasts .

ABC News
40 minutes ago
- ABC News
Coroner finds Rachael Dixon's death at wellness retreat 'in the context' of taking magic mushrooms
A coroner's report into the death of a woman who consumed magic mushrooms at a regional Victorian wellness retreat has found no clear cause of death. However, Coroner Audrey Jamieson said there was a possibility that Rachael Dixon died from psylocibin use. "I find that her death occurred in the context of her recent use of illicit drugs," the coroner concluded. The 53-year-old Melbourne woman died in April 2024 when she became unresponsive after drinking two serves of mushroom tea at a private retreat at Soul Barn in Clunes, a few hours north-west of Melbourne. Post-mortem toxicological analysis found Ms Dixon had approximately 6 ng/mL of psilocybin in her system at the time of death. The event was run by Deanne Matthews, who pleaded guilty in March to trafficking a drug of dependence, but did not receive a conviction. Ms Matthews, who rented the venue for her retreats, is not facing any charges in relation to Ms Dixon's death. The coroner's report, published on Monday, detailed how Ms Dixon, who had "always struggled with mental health problems", was a regular attendee at Ms Matthew's retreats. The coroner noted that Ms Dixon and Ms Matthews had known each other for around eight years — a relationship based on "healing". In 2022, Ms Dixon paid $500 for a copy of Ms Matthew's "Deep Self 28 Day Microdosing Experience", which contained journalling prompts and information on how to use and dose psilocybin at home. Annotations from the journal revealed that Ms Dixon's primary goal was "no binge drinking alcohol and food". The coroner said not only was there evidence to suggest Ms Dixon saw psilocybin as a means to deal with past traumas, but she relied on Ms Matthew for advice. In the 18 months leading up to her death, Ms Dixon attended the Clunes retreats about six times. The report said that on the evening of 14 April 2024, before the healing session began, fellow participants recalled that Ms Dixon was "on a high". "I'm meeting myself, I'm going home," one of Ms Dixon's fellow participants remembered her saying. According to the coroner's report, about five hours after Ms Dixon's first dose of mushroom tea, Ms Matthews reported she "was crying" and concluded she "needed some fresh air". Ms Matthews reportedly moved her to the kitchen, laid her on a pillow and opened the back door. Just before midnight, Ms Matthews contacted emergency services, telling an operator that Ms Dixon was "not responding". Ms Dixon was declared dead by attending paramedics soon after. While the report found no clear medical cause of death, it cited research from the Australian Psychedelic Society on "wood-lover paralysis" — a condition of muscle weakness linked to the consumption of psilocybin. The coroner concluded there was a "temporal relationship" between Ms Dixon's death and the consumption of the magic mushroom tea. The coroner said that while Ms Dixon suffered symptoms that appeared consistent with wood-lover paralysis — including her inability to walk and her loss of spontaneous breathing — it was not something that could "be ascertained forensically". "I ultimately determined on the balance of probabilities that I am unable to find wood-lover paralysis caused or contributed to Rachel's death," the coroner said. The coroner made no formal recommendations, but said the most appropriate intervention was "user education". "Rachael's case reflects that we do not know enough at present about the chemistry and pharmacology of magic mushrooms to confirm or exclude that mushroom consumption caused or contributed to her death," the coroner said.